請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/2538
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 郭遠燁(Yuan-Yeh Kuo) | |
dc.contributor.author | Ken-Hong Lim | en |
dc.contributor.author | 林建鴻 | zh_TW |
dc.date.accessioned | 2021-05-13T06:41:40Z | - |
dc.date.available | 2017-09-12 | |
dc.date.available | 2021-05-13T06:41:40Z | - |
dc.date.copyright | 2017-09-12 | |
dc.date.issued | 2017 | |
dc.date.submitted | 2017-06-13 | |
dc.identifier.citation | 1. Tefferi A, Thiele J, Vardiman JW. The 2008 World Health Organization classification system for myeloproliferative neoplasms: order out of chaos. Cancer 2009;115:3842-7.
2. Tefferi A, Vainchenker W. Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies. J Clin Oncol 2011;29:573-82. 3. Passamonti F, Rumi E, Pungolino E, Malabarba L, Bertazzoni P, Valentini M, Orlandi E, Arcaini L, Brusamolino E, Pascutto C, Cazzola M, Morra E, Lazzarino M. Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am J Med 2004;117:755-61. 4. Tefferi A. Primary myelofibrosis: 2014 update on diagnosis, risk-stratification, and management. Am J Hematol 2014;89:915-25. 5. Campbell PJ, Scott LM, Buck G, Wheatley K, East CL, Marsden JT, Duffy A, Boyd EM, Bench AJ, Scott MA, Vassiliou GS, Milligan DW, Smith SR, Erber WN, Bareford D, Wilkins BS, Reilly JT, Harrison CN, Green AR. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet 2005;366:1945-53. 6. Tefferi A. Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management. Am J Hematol 2013;88:141-50. 7. Lin H-C, Chen CG-S, Chang M-C, Wang W-T, Kao CW, Lo A-C, Su N-W, Chang Y-C, Chiang Y-H, Chou K-F, Liao P-N, Cai G-J, Cheng H-I, Lin J, Chang Y-F, Hsieh R-K, Lim K-H. JAK2 V617F mutation in adult Taiwanese patients with essential thrombocythemia: More prevalent in old patient and correlated with higher hemoglobin level and higher leukocyte count. Int J Gerontol 2013;7:40-4. 8. Pardanani AD, Levine RL, Lasho T, Pikman Y, Mesa RA, Wadleigh M, Steensma DP, Elliott MA, Wolanskyj AP, Hogan WJ, McClure RF, Litzow MR, Gilliland DG, Tefferi A. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood 2006;108:3472-6. 9. Lin H-C, Wang S-C, Chen CG-S, Chang M-C, Wang W-T, Su N-W, Cheng H-I, Lin J, Chang Y-F, Hsieh R-K, Chang C-C, Hwang Y, Lim K-H, Kuo Y-Y. Mutation and lineage analysis of DNMT3A in BCR-ABL1-negative chronic myeloproliferative neoplasms. Int J Gerontol 2013;7:186-8. 10. Lundberg P, Karow A, Nienhold R, Looser R, Hao-Shen H, Nissen I, Girsberger S, Lehmann T, Passweg J, Stern M, Beisel C, Kralovics R, Skoda RC. Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms. Blood 2014;123:2220-8. 11. Guglielmelli P, Nangalia J, Green AR, Vannucchi AM. CALR mutations in myeloproliferative neoplasms: hidden behind the reticulum. Am J Hematol 2014;89:453-6. 12. Michalak M, Groenendyk J, Szabo E, Gold LI, Opas M. Calreticulin, a multi-process calcium-buffering chaperone of the endoplasmic reticulum. Biochem J 2009;417:651-66. 13. Chao MP, Majeti R, Weissman IL. Programmed cell removal: a new obstacle in the road to developing cancer. Nat Rev Cancer 2012;12:58-67. 14. Gold LI, Eggleton P, Sweetwyne MT, Van Duyn LB, Greives MR, Naylor SM, Michalak M, Murphy-Ullrich JE. Calreticulin: non-endoplasmic reticulum functions in physiology and disease. FASEB J 2010;24:665-83. 15. Tesniere A, Apetoh L, Ghiringhelli F, Joza N, Panaretakis T, Kepp O, Schlemmer F, Zitvogel L, Kroemer G. Immunogenic cancer cell death: a key-lock paradigm. Curr Opin Immunol 2008;20:504-11. 16. Zhang T, Xia Y, Zhang L, Bao W, Hong C, Gao XM. CD1d(hi)CD5(+) B cells differentiate into antibody-secreting cells under the stimulation with calreticulin fragment. Protein Cell 2013;4:872-81. 17. Hong C, Zhang T, Gao XM. Recombinant murine calreticulin fragment 39-272 expands CD1d(hi)CD5+ IL-10-secreting B cells that modulate experimental autoimmune encephalomyelitis in C57BL/6 mice. Mol Immunol 2013;55:237-46. 18. Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD, Them NC, Berg T, Gisslinger B, Pietra D, Chen D, Vladimer GI, Bagienski K, Milanesi C, Casetti IC, Sant'Antonio E, Ferretti V, Elena C, Schischlik F, Cleary C, Six M, Schalling M, Schonegger A, Bock C, Malcovati L, Pascutto C, Superti-Furga G, Cazzola M, Kralovics R. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med 2013;369:2379-90. 19. Nangalia J, Massie CE, Baxter EJ, Nice FL, Gundem G, Wedge DC, Avezov E, Li J, Kollmann K, Kent DG, Aziz A, Godfrey AL, Hinton J, Martincorena I, Van Loo P, Jones AV, Guglielmelli P, Tarpey P, Harding HP, Fitzpatrick JD, Goudie CT, Ortmann CA, Loughran SJ, Raine K, Jones DR, Butler AP, Teague JW, O'Meara S, McLaren S, Bianchi M, Silber Y, Dimitropoulou D, Bloxham D, Mudie L, Maddison M, Robinson B, Keohane C, Maclean C, Hill K, Orchard K, Tauro S, Du MQ, Greaves M, Bowen D, Huntly BJ, Harrison CN, Cross NC, Ron D, Vannucchi AM, Papaemmanuil E, Campbell PJ, Green AR. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med 2013;369:2391-405. 20. Nangalia J, Green TR. The evolving genomic landscape of myeloproliferative neoplasms. ASH Education Program Book 2014;2014:287-96. 21. Green MR, Gentles AJ, Nair RV, Irish JM, Kihira S, Liu CL, Kela I, Hopmans ES, Myklebust JH, Ji H, Plevritis SK, Levy R, Alizadeh AA. Hierarchy in somatic mutations arising during genomic evolution and progression of follicular lymphoma. Blood 2013;121:1604-11. 22. Lasho TL, Elliott MA, Pardanani A, Tefferi A. CALR mutation studies in chronic neutrophilic leukemia. Am J Hematol 2014;89:450. 23. Tefferi A, Thiele J, Vannucchi AM, Barbui T. An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms. Leukemia 2014;28:1407-13. 24. Passamonti F, Maffioli M. Update from the latest WHO classification of MPNs: a user's manual. Hematology Am Soc Hematol Educ Program 2016;2016:534-42. 25. Soler G, Bernal-Vicente A, Anton AI, Torregrosa JM, Caparros-Perez E, Sanchez-Serrano I, Martinez-Perez A, Sanchez-Vega B, Vicente V, Ferrer-Marin F. The JAK2 46/1 haplotype does not predispose to CALR-mutated myeloproliferative neoplasms. Ann Hematol 2014. 26. Vannucchi AM, Rotunno G, Bartalucci N, Raugei G, Carrai V, Balliu M, Mannarelli C, Pacilli A, Calabresi L, Fjerza R, Pieri L, Bosi A, Manfredini R, Guglielmelli P. Calreticulin mutation-specific immunostaining in myeloproliferative neoplasms: pathogenetic insight and diagnostic value. Leukemia 2014;28:1811-8. 27. Chi J, Nicolaou KA, Nicolaidou V, Koumas L, Mitsidou A, Pierides C, Manoloukos M, Barbouti K, Melanthiou F, Prokopiou C, Vassiliou GS, Costeas P. Calreticulin gene exon 9 frameshift mutations in patients with thrombocytosis. Leukemia 2013;28:1152-4. 28. Bilbao-Sieyro C, Santana G, Moreno M, Torres L, Santana-Lopez G, Rodriguez-Medina C, Perera M, Bellosillo B, de la Iglesia S, Molero T, Gomez-Casares MT. High resolution melting analysis: a rapid and accurate method to detect CALR mutations. PLoS One 2014;9:e103511. 29. Rotunno G, Mannarelli C, Guglielmelli P, Pacilli A, Pancrazzi A, Pieri L, Fanelli T, Bosi A, Vannucchi AM, Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative I. Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia. Blood 2014;123:1552-5. 30. Rumi E, Pietra D, Ferretti V, Klampfl T, Harutyunyan AS, Milosevic JD, Them NC, Berg T, Elena C, Casetti IC, Milanesi C, Sant'antonio E, Bellini M, Fugazza E, Renna MC, Boveri E, Astori C, Pascutto C, Kralovics R, Cazzola M, Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative I. JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. Blood 2014;123:1544-51. 31. Chao MP, Gotlib J. Two faces of ET: CALR and JAK2. Blood 2014;123:1438-40. 32. Tefferi A, Lasho TL, Finke CM, Knudson RA, Ketterling R, Hanson CH, Maffioli M, Caramazza D, Passamonti F, Pardanani A. CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons. Leukemia 2014;28:1472-7. 33. Tefferi A, Guglielmelli P, Lasho TL, Rotunno G, Finke C, Mannarelli C, Belachew AA, Pancrazzi A, Wassie EA, Ketterling RP, Hanson CA, Pardanani A, Vannucchi AM. CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients. Leukemia 2014;28:1494-500. 34. Guglielmelli P, Lasho TL, Rotunno G, Score J, Mannarelli C, Pancrazzi A, Biamonte F, Pardanani A, Zoi K, Reiter A, Duncombe A, Fanelli T, Pietra D, Rumi E, Finke C, Gangat N, Ketterling RP, Knudson RA, Hanson CA, Bosi A, Pereira A, Manfredini R, Cervantes F, Barosi G, Cazzola M, Cross NC, Vannucchi AM, Tefferi A. The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients. Leukemia 2014;28:1804-10. 35. Tefferi A, Lasho TL, Tischer A, Wassie EA, Finke CM, Belachew AA, Ketterling RP, Hanson CA, Pardanani AD. The prognostic advantage of calreticulin mutations in myelofibrosis might be confined to type 1 or type 1-like CALR variants. Blood 2014;124:2465-6. 36. Shivarov V, Ivanova M, Tiu RV. Mutated calreticulin retains structurally disordered C terminus that cannot bind Ca(2+): some mechanistic and therapeutic implications. Blood Cancer J 2014;4:e185. 37. Rampal R, Al-Shahrour F, Abdel-Wahab O, Patel JP, Brunel JP, Mermel CH, Bass AJ, Pretz J, Ahn J, Hricik T, Kilpivaara O, Wadleigh M, Busque L, Gilliland DG, Golub TR, Ebert BL, Levine RL. Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis. Blood 2014;123:e123-33. 38. Kollmann K, Nangalia J, Warsch W, Quentmeier H, Bench A, Boyd E, Scott M, Drexler HG, Green AR. MARIMO cells harbor a CALR mutation but are not dependent on JAK2/STAT5 signaling. Leukemia 2014. 39. Araki M, Yang Y, Masubuchi N, Hironaka Y, Takei H, Morishita S, Mizukami Y, Kan S, Shirane S, Edahiro Y, Sunami Y, Ohsaka A, Komatsu N. Activation of the thrombopoietin receptor by mutant calreticulin in CALR-mutant myeloproliferative neoplasms. Blood 2016;127:1307-16. 40. Marty C, Pecquet C, Nivarthi H, El-Khoury M, Chachoua I, Tulliez M, Villeval JL, Raslova H, Kralovics R, Constantinescu SN, Plo I, Vainchenker W. Calreticulin mutants in mice induce an MPL-dependent thrombocytosis with frequent progression to myelofibrosis. Blood 2016;127:1317-24. 41. Chachoua I, Pecquet C, El-Khoury M, Nivarthi H, Albu RI, Marty C, Gryshkova V, Defour JP, Vertenoeil G, Ngo A, Koay A, Raslova H, Courtoy PJ, Choong ML, Plo I, Vainchenker W, Kralovics R, Constantinescu SN. Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants. Blood 2016;127:1325-35. 42. Elf S, Abdelfattah NS, Chen E, Perales-Paton J, Rosen EA, Ko A, Peisker F, Florescu N, Giannini S, Wolach O, Morgan EA, Tothova Z, Losman JA, Schneider RK, Al-Shahrour F, Mullally A. Mutant Calreticulin Requires Both Its Mutant C-terminus and the Thrombopoietin Receptor for Oncogenic Transformation. Cancer Discov 2016;6:368-81. 43. Nivarthi H, Chen D, Cleary C, Kubesova B, Jager R, Bogner E, Marty C, Pecquet C, Vainchenker W, Constantinescu SN, Kralovics R. Thrombopoietin receptor is required for the oncogenic function of CALR mutants. Leukemia 2016;30:1759-63. 44. Xu J, Du L, Wen Z. Myelopoiesis during zebrafish early development. J Genet Genomics 2012;39:435-42. 45. Teittinen KJ, Gronroos T, Parikka M, Ramet M, Lohi O. The zebrafish as a tool in leukemia research. Leuk Res 2012;36:1082-8. 46. Forrester AM, Berman JN, Payne EM. Myelopoiesis and myeloid leukaemogenesis in the zebrafish. Adv Hematol 2012;2012:358518. 47. Sabaawy HE, Azuma M, Embree LJ, Tsai HJ, Starost MF, Hickstein DD. TEL-AML1 transgenic zebrafish model of precursor B cell acute lymphoblastic leukemia. Proc Natl Acad Sci U S A 2006;103:15166-71. 48. Langenau DM, Traver D, Ferrando AA, Kutok JL, Aster JC, Kanki JP, Lin S, Prochownik E, Trede NS, Zon LI, Look AT. Myc-induced T cell leukemia in transgenic zebrafish. Science 2003;299:887-90. 49. Etchin J, Kanki JP, Look AT. Zebrafish as a model for the study of human cancer. Methods Cell Biol 2011;105:309-37. 50. Rennekamp AJ, Peterson RT. 15 years of zebrafish chemical screening. Curr Opin Chem Biol 2014;24C:58-70. 51. Bill BR, Petzold AM, Clark KJ, Schimmenti LA, Ekker SC. A primer for morpholino use in zebrafish. Zebrafish 2009;6:69-77. 52. Sander JD, Cade L, Khayter C, Reyon D, Peterson RT, Joung JK, Yeh JR. Targeted gene disruption in somatic zebrafish cells using engineered TALENs. Nat Biotechnol 2011;29:697-8. 53. Huang P, Xiao A, Zhou M, Zhu Z, Lin S, Zhang B. Heritable gene targeting in zebrafish using customized TALENs. Nat Biotechnol 2011;29:699-700. 54. Bedell VM, Wang Y, Campbell JM, Poshusta TL, Starker CG, Krug RG, 2nd, Tan W, Penheiter SG, Ma AC, Leung AY, Fahrenkrug SC, Carlson DF, Voytas DF, Clark KJ, Essner JJ, Ekker SC. In vivo genome editing using a high-efficiency TALEN system. Nature 2012;491:114-8. 55. Hruscha A, Krawitz P, Rechenberg A, Heinrich V, Hecht J, Haass C, Schmid B. Efficient CRISPR/Cas9 genome editing with low off-target effects in zebrafish. Development 2013;140:4982-7. 56. Hwang WY, Fu Y, Reyon D, Maeder ML, Kaini P, Sander JD, Joung JK, Peterson RT, Yeh JR. Heritable and precise zebrafish genome editing using a CRISPR-Cas system. PLoS One 2013;8:e68708. 57. Xiao A, Wang Z, Hu Y, Wu Y, Luo Z, Yang Z, Zu Y, Li W, Huang P, Tong X, Zhu Z, Lin S, Zhang B. Chromosomal deletions and inversions mediated by TALENs and CRISPR/Cas in zebrafish. Nucleic Acids Res 2013;41:e141. 58. Hwang WY, Fu Y, Reyon D, Maeder ML, Tsai SQ, Sander JD, Peterson RT, Yeh JR, Joung JK. Efficient genome editing in zebrafish using a CRISPR-Cas system. Nat Biotechnol 2013;31:227-9. 59. Wei C, Liu J, Yu Z, Zhang B, Gao G, Jiao R. TALEN or Cas9 - rapid, efficient and specific choices for genome modifications. J Genet Genomics 2013;40:281-9. 60. Mosimann C, Zon LI. Advanced zebrafish transgenesis with Tol2 and application for Cre/lox recombination experiments. Methods Cell Biol 2011;104:173-94. 61. Moore FE, Langenau DM. Through the looking glass: visualizing leukemia growth, migration, and engraftment using fluorescent transgenic zebrafish. Adv Hematol 2012;2012:478164. 62. Liu CC, Wang SC, Kao CW, Hsieh RK, Chang MC, Chang YF, Lim KH, Chen CG. B cells facilitate platelet production mediated by cytokines in patients with essential thrombocythaemia. Thromb Haemost 2014;112:537-50. 63. Lim K-H, Lin H-C, Chiang Y-H, Wang W-T, Lin C-S, Chang Y-C, Su N-W, Chen CG-S, Lin J, Hsieh R-K, Chang M-C, Chang Y-F, Kuo Y-Y, Chou W-C. Calr mutations in essential thrombocythemia: frequency, clinical correlation and screening by high-resolution melting analysis. Blood 2014;124:1838. 64. Chen CC, Gau JP, Chou HJ, You JY, Huang CE, Chen YY, Lung J, Chou YS, Leu YW, Lu CH, Lee KD, Tsai YH. Frequencies, clinical characteristics, and outcome of somatic CALR mutations in JAK2-unmutated essential thrombocythemia. Ann Hematol 2014. 65. Lim K-H, Lin H-C, Gon-Shen Chen C, Chiang Y-H, Hsiao C-D, Kuo Y-Y. CALR mutations in myeloproliferative neoplasms. Int J Gerontol 2014;8:105. 66. Rotunno G, Mannarelli C, Guglielmelli P, Pacilli A, Pancrazzi A, Pieri L, Fanelli T, Bosi A, Vannucchi A. Impact of Calreticulin Mutations on Clinical and Hematological Phenotype and Outcome in Essential Thrombocythemia. Blood 2013;123:1552-5. 67. Lim K-H, Lin H-C, Chen CG-S, Chiang Y-H, Hsiao C-D, Kuo Y-Y. CALR Mutations in Myeloproliferative Neoplasms. Int J Gerontol 2014;8:105. 68. Vossen RH, Aten E, Roos A, den Dunnen JT. High-resolution melting analysis (HRMA): more than just sequence variant screening. Hum Mutat 2009;30:860-6. 69. Er TK, Lin SF, Chang JG, Hsieh LL, Lin SK, Wang LH, Lin CW, Chang CS, Liu TC. Detection of the JAK2 V617F missense mutation by high resolution melting analysis and its validation. Clin Chim Acta 2009;408:39-44. 70. Qian J, Lin J, Yao DM, Chen Q, Xiao GF, Ji RB, Li Y, Yang J, Qian Z. Rapid detection of JAK2 V617F mutation using high-resolution melting analysis with LightScanner platform. Clin Chim Acta 2010;411:2097-100. 71. Rapado I, Grande S, Albizua E, Ayala R, Hernandez JA, Gallardo M, Gilsanz F, Martinez-Lopez J. High resolution melting analysis for JAK2 Exon 14 and Exon 12 mutations: a diagnostic tool for myeloproliferative neoplasms. J Mol Diagn 2009;11:155-61. 72. Wu Z, Zhang X, Xu X, Chen Y, Hu T, Kang Z, Li S, Wang H, Liu W, Ma X, Guan M. The mutation profile of JAK2 and CALR in Chinese Han patients with Philadelphia chromosome-negative myeloproliferative neoplasms. J Hematol Oncol 2014;7:48. 73. Lim KH, Lin HC, Chen CG, Wang WT, Chang YC, Chiang YH, Lin CS, Su NW, Su YW, Lin J, Chang YF, Chang MC, Hsieh RK, Kuo YY, Chou WC. Rapid and sensitive detection of CALR exon 9 mutations using high-resolution melting analysis. Clin Chim Acta 2015;440:133-9. 74. Shirane S, Araki M, Morishita S, Edahiro Y, Takei H, Yoo Y, Choi M, Sunami Y, Hironaka Y, Noguchi M, Koike M, Noda N, Ohsaka A, Komatsu N. JAK2, CALR, and MPL mutation spectrum in Japanese myeloproliferative neoplasms patients. Haematologica 2014. 75. Fu R, Xuan M, Zhou Y, Sun T, Bai J, Cao Z, Zhang L, Li H, Zhang D, Zhang X, Lv C, Xue F, Liu X, Yang R, Zhang L. Analysis of calreticulin mutations in Chinese patients with essential thrombocythemia: clinical implications in diagnosis, prognosis and treatment. Leukemia 2014;28:1912-4. 76. Chen CC, Gau JP, Chou HJ, You JY, Huang CE, Chen YY, Lung J, Chou YS, Leu YW, Lu CH, Lee KD, Tsai YH. Frequencies, clinical characteristics, and outcome of somatic CALR mutations in JAK2-unmutated essential thrombocythemia. Ann Hematol 2014;93:2029-36. 77. Wang Y, Ho AK, Pan Q, Racke FK, Jones D. In-frame exon 9 CALR deletions co-occur with other alterations in the JAK-STAT pathway in myeloproliferative neoplasms. Blood 2014;56th ASH Annual Meeting Abstract 4588. 78. James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C, Garcon L, Raslova H, Berger R, Bennaceur-Griscelli A, Villeval JL, Constantinescu SN, Casadevall N, Vainchenker W. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005;434:1144-8. 79. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, Vassiliou GS, Bench AJ, Boyd EM, Curtin N, Scott MA, Erber WN, Green AR, Cancer Genome P. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005;365:1054-61. 80. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, Tichelli A, Cazzola M, Skoda RC. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005;352:1779-90. 81. Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ, Boggon TJ, Wlodarska I, Clark JJ, Moore S, Adelsperger J, Koo S, Lee JC, Gabriel S, Mercher T, D'Andrea A, Frohling S, Dohner K, Marynen P, Vandenberghe P, Mesa RA, Tefferi A, Griffin JD, Eck MJ, Sellers WR, Meyerson M, Golub TR, Lee SJ, Gilliland DG. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005;7:387-97. 82. Lu X, Levine R, Tong W, Wernig G, Pikman Y, Zarnegar S, Gilliland DG, Lodish H. Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation. Proc Natl Acad Sci U S A 2005;102:18962-7. 83. Lim KH, Chang YC, Gon-Shen Chen C, Lin HC, Wang WT, Chiang YH, Cheng HI, Su NW, Lin J, Chang YF, Chang MC, Hsieh RK, Kuo YY, Chou WC. Frequent CALR exon 9 alterations in JAK2 V617F-mutated essential thrombocythemia detected by high-resolution melting analysis. Blood Cancer J 2015;5:e295. 84. Lim KH, Chang YC, Chiang YH, Lin HC, Chang CY, Lin CS, Huang L, Wang WT, Gon-Shen Chen C, Chou WC, Kuo YY. Expression of CALR mutants causes mpl-dependent thrombocytosis in zebrafish. Blood Cancer J 2016;6:e481. 85. Shide K, Kameda T, Yamaji T, Sekine M, Inada N, Kamiunten A, Akizuki K, Nakamura K, Hidaka T, Kubuki Y, Shimoda H, Kitanaka A, Honda A, Sawaguchi A, Abe H, Miike T, Iwakiri H, Tahara Y, Sueta M, Hasuike S, Yamamoto S, Nagata K, Shimoda K. Calreticulin mutant mice develop essential thrombocythemia that is ameliorated by the JAK inhibitor ruxolitinib. Leukemia 2016. 86. Lin H-C, Chen CG-S, Chang M-C, Wang W-T, Kao CW, Lo A-C, Su N-W, Chang Y-C, Chiang Y-H, Chou K-F, Liao P-N, Cai G-J, Cheng H-I, Lin J, Chang Y-F, Hsieh R-K, Lim K-H. JAK2 V617F mutation in adult Taiwanese patients with essential thrombocythemia: more prevalent in old patients and correlated with higher hemoglobin level and higher leukocyte count. Int J Gerontol 2013;7:40-4. 87. Li S, Kralovics R, De Libero G, Theocharides A, Gisslinger H, Skoda RC. Clonal heterogeneity in polycythemia vera patients with JAK2 exon12 and JAK2-V617F mutations. Blood 2008;111:3863-6. 88. Lin H-C, Wang S-C, Chen CG-S, Chang M-C, Wang W-T, Su N-W, Cheng H-I, Lin J, Chang Y-F, Hsieh R-K, Chang C-C, Hwang Y, Lim K-H, Kuo Y-Y. Mutation and lineage analysis of DNMT3A in BCR-ABL1-negative chronic myeloproliferative neoplasms. Int J Gerontol 2013;7:186-8. 89. Wu Z, Zhang X, Xu X, Chen Y, Hu T, Kang Z, Li S, Wang H, Liu W, Ma X, Guan M. The mutation profile of JAK2 and CALR in Chinese Han patients with Philadelphia chromosome-negative myeloproliferative neoplasms. J Hematol Oncol 2014;7:48. 90. Tefferi A, Wassie EA, Guglielmelli P, Gangat N, Belachew AA, Lasho TL, Finke C, Ketterling RP, Hanson CA, Pardanani A, Wolanskyj AP, Maffioli M, Casalone R, Pacilli A, Vannucchi AM, Passamonti F. Type 1 versus Type 2 calreticulin mutations in essential thrombocythemia: a collaborative study of 1027 patients. Am J Hematol 2014;89:E121-4. 91. Tefferi A, Wassie EA, Lasho TL, Finke C, Belachew AA, Ketterling RP, Hanson CA, Pardanani A, Gangat N, Wolanskyj AP. Calreticulin mutations and long-term survival in essential thrombocythemia. Leukemia 2014;28:2300-3. 92. Shirane S, Araki M, Morishita S, Edahiro Y, Takei H, Yoo Y, Choi M, Sunami Y, Hironaka Y, Noguchi M, Koike M, Noda N, Ohsaka A, Komatsu N. JAK2, CALR, and MPL mutation spectrum in Japanese patients with myeloproliferative neoplasms. Haematologica 2015;100:e46-8. 93. Ha JS, Kim YK. Calreticulin exon 9 mutations in myeloproliferative neoplasms. Ann Lab Med 2015;35:22-7. 94. Al Assaf C, Van Obbergh F, Billiet J, Lierman E, Devos T, Graux C, Hervent AS, Emmerechts J, Tousseyn T, De Paepe P, Papadopoulos P, Michaux L, Vandenberghe P. Analysis of phenotype and outcome in essential thrombocythemia with CALR or JAK2 mutations. Haematologica 2015;100:893-7. 95. Lin Y, Liu E, Sun Q, Ma J, Li Q, Cao Z, Wang J, Jia Y, Zhang H, Song Z, Ai X, Shi L, Feng X, Li C, Wang J, Ru K. The Prevalence of JAK2, MPL, and CALR Mutations in Chinese Patients With BCR-ABL1-Negative Myeloproliferative Neoplasms. Am J Clin Pathol 2015;144:165-71. 96. Lim KH, Chang YC, Chen CG, Lin HC, Wang WT, Chiang YH, Cheng HI, Su NW, Lin J, Chang YF, Chang MC, Hsieh RK, Kuo YY, Chou WC. Frequent CALR exon 9 alterations in JAK2 V617F-mutated essential thrombocythemia detected by high-resolution melting analysis. Blood Cancer J 2015;5:e295. 97. Usseglio F, Beaufils N, Calleja A, Raynaud S, Gabert J. Detection of CALR and MPL Mutations in Low Allelic Burden JAK2 V617F Essential Thrombocythemia. J Mol Diagn 2017;19:92-8. 98. Verstovsek S, Kantarjian H, Mesa RA, Pardanani AD, Cortes-Franco J, Thomas DA, Estrov Z, Fridman JS, Bradley EC, Erickson-Viitanen S, Vaddi K, Levy R, Tefferi A. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med 2010;363:1117-27. 99. Pourcelot E, Trocme C, Mondet J, Bailly S, Toussaint B, Mossuz P. Cytokine profiles in polycythemia vera and essential thrombocythemia patients: clinical implications. Exp Hematol 2014;42:360-8. 100. Rawlings DJ, Schwartz MA, Jackson SW, Meyer-Bahlburg A. Integration of B cell responses through Toll-like receptors and antigen receptors. Nat Rev Immunol 2012;12:282-94. 101. Manetta J, Bina H, Ryan P, Fox N, Witcher DR, Kikly K. Generation and characterization of tabalumab, a human monoclonal antibody that neutralizes both soluble and membrane-bound B-cell activating factor. J Inflamm Res 2014;7:121-31. 102. Cahu X, Constantinescu SN. Oncogenic Drivers in Myeloproliferative Neoplasms: From JAK2 to Calreticulin Mutations. Curr Hematol Malig Rep 2015;10:335-43. 103. Sangkhae V, Etheridge SL, Kaushansky K, Hitchcock IS. The thrombopoietin receptor, MPL, is critical for development of a JAK2V617F-induced myeloproliferative neoplasm. Blood 2014;124:3956-63. 104. Papadantonakis N, Matsuura S, Ravid K. Megakaryocyte pathology and bone marrow fibrosis: the lysyl oxidase connection. Blood 2012;120:1774-81. 105. Balduini A, Badalucco S, Pugliano MT, Baev D, De Silvestri A, Cattaneo M, Rosti V, Barosi G. In vitro megakaryocyte differentiation and proplatelet formation in Ph-negative classical myeloproliferative neoplasms: distinct patterns in the different clinical phenotypes. PLoS One 2011;6:e21015. 106. Hobbs CM, Manning H, Bennett C, Vasquez L, Severin S, Brain L, Mazharian A, Guerrero JA, Li J, Soranzo N, Green AR, Watson SP, Ghevaert C. JAK2V617F leads to intrinsic changes in platelet formation and reactivity in a knock-in mouse model of essential thrombocythemia. Blood 2013;122:3787-97. 107. Kollmann K, Warsch W, Gonzalez-Arias C, Nice FL, Avezov E, Milburn J, Li J, Dimitropoulou D, Biddie S, Wang M, Poynton E, Colzani M, Tijssen MR, Anand S, McDermott U, Huntly B, Green T. A novel signalling screen demonstrates that CALR mutations activate essential MAPK signalling and facilitate megakaryocyte differentiation. Leukemia 2017 in press. 108. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, Harris NL, Le Beau MM, Hellstrom-Lindberg E, Tefferi A, Bloomfield CD. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009;114:937-51. 109. Cazzola M, Kralovics R. From Janus kinase 2 to calreticulin: the clinically relevant genomic landscape of myeloproliferative neoplasms. Blood 2014;123:3714-9. 110. Caramelo JJ, Parodi AJ. Getting in and out from calnexin/calreticulin cycles. J Biol Chem 2008;283:10221-5. 111. Rasighaemi P, Basheer F, Liongue C, Ward AC. Zebrafish as a model for leukemia and other hematopoietic disorders. J Hematol Oncol 2015;8:29. 112. Onnebo SM, Rasighaemi P, Kumar J, Liongue C, Ward AC. Alternative TEL-JAK2 fusions associated with T-cell acute lymphoblastic leukemia and atypical chronic myelogenous leukemia dissected in zebrafish. Haematologica 2012;97:1895-903. 113. Lu JW, Hsieh MS, Liao HA, Yang YJ, Ho YJ, Lin LI. Zebrafish as a Model for the Study of Human Myeloid Malignancies. Biomed Res Int 2015;2015:641475. 114. Zhang B, Shimada Y, Kuroyanagi J, Nishimura Y, Umemoto N, Nomoto T, Shintou T, Miyazaki T, Tanaka T. Zebrafish xenotransplantation model for cancer stem-like cell study and high-throughput screening of inhibitors. Tumour Biol 2014;35:11861-9. 115. Ridges S, Heaton WL, Joshi D, Choi H, Eiring A, Batchelor L, Choudhry P, Manos EJ, Sofla H, Sanati A, Welborn S, Agarwal A, Spangrude GJ, Miles RR, Cox JE, Frazer JK, Deininger M, Balan K, Sigman M, Muschen M, Perova T, Johnson R, Montpellier B, Guidos CJ, Jones DA, Trede NS. Zebrafish screen identifies novel compound with selective toxicity against leukemia. Blood 2012;119:5621-31. 116. Morash MG, Douglas SE, Robotham A, Ridley CM, Gallant JW, Soanes KH. The zebrafish embryo as a tool for screening and characterizing pleurocidin host-defense peptides as anti-cancer agents. Dis Model Mech 2011;4:622-33. 117. Lin HF, Traver D, Zhu H, Dooley K, Paw BH, Zon LI, Handin RI. Analysis of thrombocyte development in CD41-GFP transgenic zebrafish. Blood 2005;106:3803-10. 118. Lawson ND, Weinstein BM. In vivo imaging of embryonic vascular development using transgenic zebrafish. Dev Biol 2002;248:307-18. 119. Westerfield M. The zebrafish book: a guide for the laboratory use of zebrafish (Danio rerio). 4th ed. Eugene, Oregon, USA: University of Oregon Press 2000. 120. Kimmel CB, Ballard WW, Kimmel SR, Ullmann B, Schilling TF. Stages of embryonic development of the zebrafish. Dev Dyn 1995;203:253-310. 121. National Center for Biotechnology Information Map Viewer. (Accessed March, 2016, at http://www.ncbi.nlm.nih.gov.ezp-prod1.hul.harvard.edu/mapview/.) 122. Flicek P, Amode MR, Barrell D, Beal K, Billis K, Brent S, Carvalho-Silva D, Clapham P, Coates G, Fitzgerald S, Gil L, Giron CG, Gordon L, Hourlier T, Hunt S, Johnson N, Juettemann T, Kahari AK, Keenan S, Kulesha E, Martin FJ, Maurel T, McLaren WM, Murphy DN, Nag R, Overduin B, Pignatelli M, Pritchard B, Pritchard E, Riat HS, Ruffier M, Sheppard D, Taylor K, Thormann A, Trevanion SJ, Vullo A, Wilder SP, Wilson M, Zadissa A, Aken BL, Birney E, Cunningham F, Harrow J, Herrero J, Hubbard TJ, Kinsella R, Muffato M, Parker A, Spudich G, Yates A, Zerbino DR, Searle SM. Ensembl 2014. Nucleic Acids Res 2014;42:D749-55. 123. Catchen JM, Conery JS, Postlethwait JH. Automated identification of conserved synteny after whole-genome duplication. Genome Res 2009;19:1497-505. 124. Sievers F, Wilm A, Dineen D, Gibson TJ, Karplus K, Li W, Lopez R, McWilliam H, Remmert M, Soding J, Thompson JD, Higgins DG. Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega. Mol Syst Biol 2011;7:539. 125. Nicholas KB, Nicholas HB. GeneDoc: a tool for editing and annotating multiply sequence alignments. Pittsburgh Supercomputing Center's National Resource for Biomedical Supercomputing; 1997. 126. Kim JH, Lee SR, Li LH, Park HJ, Park JH, Lee KY, Kim MK, Shin BA, Choi SY. High cleavage efficiency of a 2A peptide derived from porcine teschovirus-1 in human cell lines, zebrafish and mice. PLoS One 2011;6:e18556. 127. Paffett-Lugassy N, Hsia N, Fraenkel PG, Paw B, Leshinsky I, Barut B, Bahary N, Caro J, Handin R, Zon LI. Functional conservation of erythropoietin signaling in zebrafish. Blood 2007;110:2718-26. 128. Ellett F, Pase L, Hayman JW, Andrianopoulos A, Lieschke GJ. mpeg1 promoter transgenes direct macrophage-lineage expression in zebrafish. Blood 2011;117:e49-56. 129. Khandekar G, Kim S, Jagadeeswaran P. Zebrafish thrombocytes: functions and origins. Adv Hematol 2012;2012:857058. 130. Ma CH, Leung AYH, Man KF. The role of calreticulin (Calr) in vertebrate hematopoiesis. Annual Zebrafish Disease Models Conference, ZDM-82015. 131. Cabagnols X, Defour JP, Ugo V, Ianotto JC, Mossuz P, Mondet J, Girodon F, Alexandre JH, Mansier O, Viallard JF, Lippert E, Murati A, Mozziconacci MJ, Saussoy P, Vekemans MC, Knoops L, Pasquier F, Ribrag V, Solary E, Plo I, Constantinescu SN, Casadevall N, Vainchenker W, Marzac C, Bluteau O. Differential association of calreticulin type 1 and type 2 mutations with myelofibrosis and essential thrombocytemia: relevance for disease evolution. Leukemia 2015;29:249-52. 132. Pietra D, Rumi E, Ferretti VV, Buduo CA, Milanesi C, Cavalloni C, Sant'Antonio E, Abbonante V, Moccia F, Casetti IC, Bellini M, Renna MC, Roncoroni E, Fugazza E, Astori C, Boveri E, Rosti V, Barosi G, Balduini A, Cazzola M. Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms. Leukemia 2016;30:431-8. 133. Balligand T, Achouri Y, Pecquet C, Chachoua I, Nivarthi H, Marty C, Vainchenker W, Plo I, Kralovics R, Constantinescu SN. Pathologic activation of thrombopoietin receptor and JAK2-STAT5 pathway by frameshift mutants of mouse calreticulin. Leukemia 2016;30:1775-8. 134. Tefferi A, Lasho TL, Finke C, Belachew AA, Wassie EA, Ketterling RP, Hanson CA, Pardanani A. Type 1 vs type 2 calreticulin mutations in primary myelofibrosis: differences in phenotype and prognost | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/2538 | - |
dc.description.abstract | 骨髓增生性腫瘤是克隆性造血幹細胞疾病,並且可以分類為“典型”和“非典型”骨髓增生性腫瘤。典型骨髓增生性腫瘤通常會在周邊的血液中表現出終端骨髓細胞的擴增,包括真性紅血血球增多症、原發性血小板增多症、原發性骨髓纖維化和慢性骨髓性白血病。近年來,在大約30%的JAK2/MPL-未突變的骨髓增生性腫瘤中發現鈣網蛋白(Calreticulin, CALR)突變。目前,鈣網蛋白突變已經成為診斷原發性血小板增多症和原發性骨髓纖維化的重要克隆標誌物。
這項研究的第一個目的是開發一種快速和敏感的篩選工具,用於檢測鈣網蛋白突變。我們使用CFX Connect即時系統成功開發了高分辨率熔解分析,以檢測原發性血小板增多症病人的鈣網蛋白第9外顯子突變。我們的高分辨率熔解分析系統在識別病人基因組DNA中的鈣網蛋白第1型和第2型突變體的最大敏感性為2.5%。我們的高分辨率熔解分析系統假陽性率為3%,並且無假陰性出現。 本研究的第二個目的是評估台灣原發性血小板增多症病人鈣網蛋白突變和JAK2 /CALR共突變的臨床和預後意義。我們在92例成年原發性血小板增多症病人中利用高分辨率熔解分析篩選了鈣網蛋白第9外顯子的改變,隨後並且進行了TA克隆。我們在21例(22.8%)病人中鑑定出典型的鈣網蛋白插入/刪除型突變。鈣網蛋白突變與年齡較輕(p = 0.025),血小板數較高(p <0.001)和較低的血紅素(p = 0.016)有相關。有趣的是,我們檢測到在59例JAK2突變的原發性血小板增多症病人中有13例(22%)的鈣網蛋白第9外顯子的改變。與這些具有JAK2 /CALR共突變的原發性血小板增多症病人有相關的因子包括年齡較大(p = 0.025),診斷後發生血栓事件較多(p = 0.048),診斷後主要動脈血栓事件較多(p = 0.022),且較多屬於血栓出血併發症高風險組病人(p = 0.023)。我們的研究顯示JAK2突變的原發性血小板增多症病人可以出現頻繁的鈣網蛋白第9外顯子的改變,並且界定出一群具有血栓事件風險增加的病人亞群。 本研究的第三個目的是要探討鈣網蛋白突變之原發性血小板增多症病人的B細胞免疫特徵。我們篩選了54例台灣成年原發性血小板增多症病人的鈣網蛋白突變並評估了其B細胞免疫特徵。在這54例原發性血小板增多症病人中有19例(35.2%)具有8種不同類型的鈣網蛋白笫9外顯子突變,其中包括4例(7.4%)同時伴有JAK2V617F共突變的病人。經過年齡、性別、追踨期和血液學參數校正後,我們進行的多變量分析證實,與健康成年人相比,活化的B細胞在JAK2突變,鈣網蛋白突變和三陰性原發性血小板增多症病人中都有增加的現象。因此,活化的B細胞增加在不同突變亞組的原發性血小板增多症病人中是一種普遍存在的現象。 本研究的第四個目的是使用斑馬魚動物模型研究鈣網蛋白突變的分子發病機制。我們確定了3種與人類鈣網蛋白直系同源的斑馬魚基因,稱為calr,calr3a和calr3b。CALR-del52和CALR-ins5突變體的表達使斑馬魚早期的造血幹/前驅細胞增加,並進而造成血小板球增多但不影響正常的血管生成。我們發現使用morpholino降低mpl但不是epor或csf3r可以顯著的減弱CALR突變體對血小板球增多的影響。此外,CALR突變體的表達也活化jak/stat信息傳遞路徑,而使用JAK抑製劑(ruxolitinib和fedratinib)可以抑制此活化現象。這些研究結果說明CALR突變體通過mpl依賴機制活化jak信息傳遞路徑導致斑馬魚致病性之血小板球生成。我們研究的結果也說明與突變型CALR腫瘤發生相關的訊息傳遞機制在人與斑馬魚之間是保守的。 | zh_TW |
dc.description.abstract | The myeloproliferative neoplasms (MPNs) are clonal hematopoietic stem cell disorders and can be classified into 'classic' and 'atypical' MPNs. Classic MPNs usually exhibit terminal myeloid cell expansion in the peripheral blood and include polycythemia vera, essential thrombocythemia (ET), primary myelofibrosis and chronic myeloid leukemia. Calreticulin (CALR) mutations have recently been discovered in about 30% JAK2/MPL-unmutated myeloproliferative neoplasms (MPN), and have become an important clonal marker for the diagnosis of essential thrombocythemia (ET) and primary myelofibrosis.
The first aim of this study is to develop a rapid and sensitive screening tool for the detection of CALR mutations. We successfully developed a high-resolution melting analysis (HRMA) with the CFX Connect real-time system to detect CALR exon 9 mutations in ET patients. The maximal sensitivity of our HRMA system in identifying both CALR type 1 and type 2 mutants from patients’ genomic DNA was 2.5%. Our HRMA has a false positive rate of 3% and no false negative. The second aim of this study is to evaluate the clinical and prognostic significance of CALR mutations and JAK2/CALR co-mutations in Taiwanese ET patients. We screened for CALR exon 9 alterations with HRMA followed by TA-cloning in 92 adult ET patients. We identified classic CALR indel mutations in 21 (22.8%) patients. CALR mutations were associated with younger age (p=0.025), higher platelet count (p<0.001) and lower hemoglobin level (p=0.016). Interestingly, we detected various CALR exon 9 alterations in 13 (22%) of 59 JAK2-mutated ET patients. JAK2-mutated ET patients with concomitant CALR alterations were associated with oldest age (p=0.025), higher thrombotic events after diagnosis (p=0.048), higher major arterial thrombotic events after diagnosis (p=0.022) and more patients being high risk group for thrombo-hemorrhagic complications (p=0.023). Frequent CALR exon 9 alterations in JAK2-mutated ET patients define a specific subgroup of patients with increased risk of thrombotic events. The third aim of this study is to determine the B cell immune profiles in CALR mutated ET patients. We screened for CALR mutations and evaluated B cell immune profiles in a cohort of 54 adult Taiwanese ET patients. 19 (35.2%) of 54 ET patients harbored 8 types of CALR exon 9 mutations including 4 (7.4%) patients with concomitant JAK2V617F mutations. Multivariate analysis adjusted for age, sex, follow-up period and hematological parameters confirmed that increased activated B cells were universally present in JAK2-mutated, CALR-mutated and triple-negative ET patients when compared to healthy adults. In conclusion, increased B cell activation is present in ET patients across different mutational subgroups. The fourth aim of this study is to investigate the molecular pathogenesis of CALR mutations using zebrafish animal models. We identified 3 zebrafish genes orthologous to human CALR, referred to as calr, calr3a and calr3b. Expression of the CALR-del52 and CALR-ins5 mutants caused an increase in the hematopoietic stem/progenitor cells followed by thrombocytosis without affecting normal angiogenesis. The expression of CALR mutants also perturbed early developmental hematopoiesis in zebrafish. Importantly, morpholino knockdown of mpl but not epor or csf3r could significantly attenuate the effects of mutant CALR. Furthermore, expression of mutant CALR caused jak-stat signaling activation in zebrafish that could be blocked by JAK inhibitors (ruxolitinib and fedratinib). These findings showed that mutant CALR activates jak-stat signaling through an mpl-dependent mechanism to mediate pathogenic thrombopoiesis in zebrafish, and illustrated that the signaling machinery related to mutant CALR tumorigenesis are conserved between human and zebrafish. | en |
dc.description.provenance | Made available in DSpace on 2021-05-13T06:41:40Z (GMT). No. of bitstreams: 1 ntu-106-D00453004-1.pdf: 11972519 bytes, checksum: 0ba0e412c0e370d60636208ae8ee47f8 (MD5) Previous issue date: 2017 | en |
dc.description.tableofcontents | 誌謝..............................................................................................................................................i
中文摘要...................................................................................................................................iii Abstract ......................................................................................................................................v Contents ..................................................................................................................................viii List of Figures ...........................................................................................................................xi List of Tables .........................................................................................................................xiii Chapter 1. Classic BCR-ABL-negative myeloproliferative neoplasms (MPNs) ……..……..…1 1. MPNs .......................................................................................................................1 1.1 Introduction of MPNs ............................................................................................1 1.2 Driver mutations in MPNs ………………………………………………….........1 2. CALR mutations in MPNs ........................................................................................2 2.1 Calreticulin .............................................................................................................2 2.2 The function of CALR …………………………………………………….……..2 2.3 CALR mutations in JAK2/MPL-unmutated essential thrombocythemia and primary myelofibrosis patients ……………………………………………………....3 2.4 Screening for CALR mutations in MPNs ...……………………………………....4 2.5 Clinical and and prognostic significance of CALR mutations ...…..……………..4 3. Molecular pathogenesis of CALR mutations in MPNs ............................................5 3.1 Mutated CALR is an initiating event in MPNs .......................................................5 3.2 Mutant CALR causes overactivation of JAK-STAT signaling …………………..5 3.3 In vitro and in vivo models of CALR mutations ……………………………...…..6 4. Zebrafish animal models ……………………...………………………………..….7 4.1 Zebrafish is a valuable model to study hematopoiesis and leukemogenesis ...…..7 4.2 Genome editing tools in zebrafish ...……………………………………………..8 5. B cell immune profiles in essential thrombocythemia patients ....……..………….8 5.1 Increased B cells activation in essential thrombocythemia patients ....…………..8 6. Aims of the study .....................................................................................................9 Chapter 2. High-resolution melting analysis as a rapid and sensitive screening tool for the detection of CALR mutations .....................................................................................11 1. Summary ................................................................................................................11 2. Introduction ............................................................................................................11 3. Patients and Methods .............................................................................................13 4. Results ....................................................................................................................16 5. Discussion ..............................................................................................................17 Chapter 3. The clinical and prognostic significance of CALR mutations and JAK2/CALR co-mutations in Taiwanese essential thrombocythemia patients ……………...........21 1. Summary ................................................................................................................21 2. Introduction ............................................................................................................22 3. Patients and Methods .............................................................................................23 4. Results ....................................................................................................................24 5. Discussion ..............................................................................................................26 Chapter 4. B cell immune profiles in CALR mutated essential thrombocythemia patients......29 1. Summary ................................................................................................................29 2. Introduction ............................................................................................................30 3. Patients and Methods .............................................................................................31 4. Results ....................................................................................................................35 5. Discussion ..............................................................................................................39 Chapter 5. The molecular pathogenesis of CALR mutations using zebrafish animal models ........................................................................................................................47 1. Summary ................................................................................................................47 2. Introduction ............................................................................................................47 3. Materials and Methods ...........................................................................................49 4. Results ....................................................................................................................52 5. Discussion ..............................................................................................................56 Chapter 6. Conclusions and future work ..................................................................................61 Figures ......................................................................................................................................63 Tables .......................................................................................................................................82 References ..............................................................................................................................106 Appendices .............................................................................................................................124 | |
dc.language.iso | en | |
dc.title | 鈣網蛋白突變在骨髓增生性腫瘤的角色 | zh_TW |
dc.title | The Roles of Calreticulin Mutations in Myeloproliferative Neoplasms | en |
dc.type | Thesis | |
dc.date.schoolyear | 105-2 | |
dc.description.degree | 博士 | |
dc.contributor.coadvisor | 周文堅(Wen-Chien Chou) | |
dc.contributor.oralexamcommittee | 徐志宏,林亮音,蕭崇德,陳功深 | |
dc.subject.keyword | B細胞,鈣網蛋白,原發性血小板增多症,高分辨率融合分析,免疫,突變,斑馬魚, | zh_TW |
dc.subject.keyword | B cell,CALR,essential thrombocythemia,high-resolution melting analysis,immune,mutation,zebrafish, | en |
dc.relation.page | 125 | |
dc.identifier.doi | 10.6342/NTU201700938 | |
dc.rights.note | 同意授權(全球公開) | |
dc.date.accepted | 2017-06-14 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 腫瘤醫學研究所 | zh_TW |
顯示於系所單位: | 腫瘤醫學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-106-1.pdf | 11.69 MB | Adobe PDF | 檢視/開啟 |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。